EP2242504A4 - Therapeutische zusammensetzungen zur behandlung entzündlicher augenerkrankungen - Google Patents

Therapeutische zusammensetzungen zur behandlung entzündlicher augenerkrankungen Download PDF

Info

Publication number
EP2242504A4
EP2242504A4 EP09701246.2A EP09701246A EP2242504A4 EP 2242504 A4 EP2242504 A4 EP 2242504A4 EP 09701246 A EP09701246 A EP 09701246A EP 2242504 A4 EP2242504 A4 EP 2242504A4
Authority
EP
European Patent Office
Prior art keywords
treatment
therapeutic compositions
inflammatory disorders
ocular inflammatory
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09701246.2A
Other languages
English (en)
French (fr)
Other versions
EP2242504A2 (de
EP2242504B1 (de
Inventor
Reza Dana
Sunil Chauhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Publication of EP2242504A2 publication Critical patent/EP2242504A2/de
Publication of EP2242504A4 publication Critical patent/EP2242504A4/de
Application granted granted Critical
Publication of EP2242504B1 publication Critical patent/EP2242504B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP09701246.2A 2008-01-09 2009-01-09 Therapeutische zusammensetzungen zur behandlung entzündlicher augenerkrankungen Active EP2242504B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1056608P 2008-01-09 2008-01-09
PCT/US2009/000114 WO2009089036A2 (en) 2008-01-09 2009-01-09 Therapeutic compositions for treatment of ocular inflammatory disorders

Publications (3)

Publication Number Publication Date
EP2242504A2 EP2242504A2 (de) 2010-10-27
EP2242504A4 true EP2242504A4 (de) 2017-05-03
EP2242504B1 EP2242504B1 (de) 2021-07-14

Family

ID=40853700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09701246.2A Active EP2242504B1 (de) 2008-01-09 2009-01-09 Therapeutische zusammensetzungen zur behandlung entzündlicher augenerkrankungen

Country Status (6)

Country Link
US (3) US9309313B2 (de)
EP (1) EP2242504B1 (de)
JP (1) JP5886523B2 (de)
AU (1) AU2009204441B2 (de)
CA (2) CA3069576A1 (de)
WO (1) WO2009089036A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
EP2385839B1 (de) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutische zusammensetzungen zur behandlung von hornhauterkrankungen
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US20110038871A1 (en) * 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
AU2011261213B2 (en) 2010-06-04 2015-05-21 Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
WO2012012184A2 (en) * 2010-06-30 2012-01-26 Johnson & Johnson Vision Care, Inc. Ophthalmic devices containing chemokine antagonists
EP3470421B9 (de) 2010-07-29 2023-10-04 Buzzard Pharmaceuticals AB Antagonisten des chimären il-1-rezeptors typ i
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9812730B2 (en) 2011-08-02 2017-11-07 Johnson & Johnson Vision Care, Inc. Biocompatible wire battery
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
EP2809660B1 (de) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur il-17-modulierung
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
US20150307619A1 (en) * 2012-12-13 2015-10-29 The Schepens Eye Research Institute, Inc. Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
EP3689348A1 (de) 2013-03-13 2020-08-05 Santen Pharmaceutical Co., Ltd. Therapeutikum für meibomdrüsendysfunktion
RU2015143521A (ru) 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
EP3287167A4 (de) 2015-04-24 2018-12-26 PHI Biomed Co., Ltd. Intelligente kontaktlinsen und intelligente brillen
WO2016178151A1 (en) * 2015-05-04 2016-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Ophthalmic contact lens with a compressible affinity matrix
WO2017120479A1 (en) * 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
EP3490581A4 (de) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. Neuromodulierende zusammensetzungen und zugehörige therapeutische verfahren zur behandlung von krebs
WO2018136551A1 (en) * 2017-01-17 2018-07-26 Tufts Medical Center, Inc. Adoptive transfer of plasmacytoid dendritic cells to prevent or treat ocular diseases and conditions
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
JP7271557B2 (ja) 2018-01-15 2023-05-11 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレータとしての縮合イミダゾール誘導体
WO2019173829A1 (en) * 2018-03-09 2019-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
JP7349491B2 (ja) 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
CN115702024A (zh) 2020-04-07 2023-02-14 Ucb生物制药有限责任公司 用作il-17调节剂的二氟环己基衍生物
MX2022014925A (es) 2020-05-27 2023-01-04 Sanofi Sa Moduladores de il-17a.
JP2023528334A (ja) 2020-05-27 2023-07-04 サノフイ Ｉｌ－１７ａモジュレーター
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022006076A1 (en) * 2020-07-01 2022-01-06 The Johns Hopkins University Ocular treatment compositions and methods
WO2022061132A1 (en) * 2020-09-17 2022-03-24 The Regents Of The University Of Colorado, A Body Corporate Ophthalmic devices for the treatment or amelioration of dry eye disease, and related methods of use
JP2023551110A (ja) 2020-11-09 2023-12-07 ユーシービー バイオファルマ エスアールエル Ｉｌ‐１７モジュレーターとしてのジシクロプロピルメチル誘導体
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
JP2023552864A (ja) 2020-12-14 2023-12-19 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレータとしてのイミダゾピリダジン誘導体
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
WO2023215269A1 (en) * 2022-05-06 2023-11-09 The Regents Of The University Of California Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity
WO2023240155A1 (en) * 2022-06-08 2023-12-14 The Schepens Eye Research Institute, Inc. Methods for treating dry eye disease
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis
WO2024115662A1 (en) 2022-12-02 2024-06-06 Leo Pharma A/S Small molecule modulators of il-17
WO2024121427A1 (en) 2022-12-09 2024-06-13 Sanofi Therapeutic compounds
GB202218860D0 (en) 2022-12-14 2023-01-25 Ucb Biopharma Sprl Therapeutic agents
GB202218846D0 (en) 2022-12-14 2023-01-25 UCB Biopharma SRL Therapeutic agents
WO2024126249A1 (en) 2022-12-14 2024-06-20 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1432724A4 (de) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
EP1562970A4 (de) 2002-11-01 2006-04-12 Univ Pennsylvania ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON HIF-1 ALPHA
CA2569867A1 (en) * 2004-06-10 2005-12-29 Zymogenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101132800A (zh) 2004-11-24 2008-02-27 席拉坎有限责任公司 一种用于眼内药物释出的植入体
EP2354160A1 (de) * 2005-08-31 2011-08-10 Schering Corporation Gentechnisch hergestellte Anti-IL-23-Antikörper
WO2007064752A2 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
BRPI0621761A2 (pt) * 2006-06-12 2011-12-20 Therakine Ltd solução oftálmica e uso de uma solução salina, e uma quantidade eficaz de pelo menos um agente terapêutico
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Anti-human Il-17 antibody", INTERNET CITATION, 28 August 2007 (2007-08-28), XP002474646, Retrieved from the Internet <URL:http://www.rndsystems.com/pdf/af317na.pdf> [retrieved on 20080327] *
"Monoclonal Anti-human IL-17 R Antibody", INTERNET CITATION, 2 April 2004 (2004-04-02), pages 1 - 2, XP002486817, Retrieved from the Internet <URL:http://www.rndsystems.com> [retrieved on 20080703] *
BARBER, L.: "Dry Eye: Closing the Treatment Gap", 15 November 2006 (2006-11-15), XP002767872, Retrieved from the Internet <URL:https://www.reviewofophthalmology.com/article/dry-eye-closing-the-treatment-gap> [retrieved on 20170307] *
See also references of WO2009089036A2 *

Also Published As

Publication number Publication date
US9309313B2 (en) 2016-04-12
US20160361412A1 (en) 2016-12-15
JP5886523B2 (ja) 2016-03-16
CA3069576A1 (en) 2009-07-16
AU2009204441B2 (en) 2015-03-05
US11241497B2 (en) 2022-02-08
CA2711696C (en) 2021-10-26
US9872901B2 (en) 2018-01-23
WO2009089036A2 (en) 2009-07-16
WO2009089036A3 (en) 2016-03-24
CA2711696A1 (en) 2009-07-16
EP2242504A2 (de) 2010-10-27
US20110104236A1 (en) 2011-05-05
EP2242504B1 (de) 2021-07-14
US20180092976A1 (en) 2018-04-05
AU2009204441A1 (en) 2009-07-16
JP2011517659A (ja) 2011-06-16

Similar Documents

Publication Publication Date Title
EP2242504A4 (de) Therapeutische zusammensetzungen zur behandlung entzündlicher augenerkrankungen
EP2187743A4 (de) Formulierungen zur behandlung von augenerkrankungen oder -leiden
IL200368A0 (en) Treatment of diseases characterized by inflammation
EP2293800A4 (de) Zusammensetzungen und verfahren zur behandlung von ohrerkrankungen
IL186578A0 (en) Compositions for treatment of neovascularization diseases
SI2120963T1 (sl) Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
HK1131047A1 (en) Treatment of inflammatory diseases
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
WO2011071995A9 (en) Compounds and methods of treating ocular disorders
IL190779A0 (en) Compositions for treatment of eye diseases
HK1160598A1 (zh) 治療腎功能紊亂的組合物和方法
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
ZA200905364B (en) Treatment of diseases characterized by inflammation
EP1988889A4 (de) Zusammensetzungen und verfahren zur behandlung von ophtamlischen erkrankungen und störungen
EP2296682B8 (de) Methoden zur behandlung von augenkrankheiten
HU0900231D0 (en) Compositions for the treatment of allergic disorders
HK1158954A1 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
EP2387565A4 (de) 2,4-pyrimidindiaminverbindungen zur behandlung von entzündungserkrankungen
GB0819446D0 (en) Treatment of inflammatory disorders
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
AU2007903299A0 (en) Treatment of ocular conditions
AU2008905378A0 (en) Compositions and methods for treatment of kidney disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100804

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20160324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20170322BHEP

Ipc: A61K 38/17 20060101AFI20170322BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190719

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/724 20060101ALI20200210BHEP

Ipc: A61K 31/728 20060101ALI20200210BHEP

Ipc: A61K 45/06 20060101ALI20200210BHEP

Ipc: C07K 14/54 20060101ALI20200210BHEP

Ipc: A61K 38/17 20060101AFI20200210BHEP

Ipc: A61K 38/20 20060101ALI20200210BHEP

Ipc: C07K 16/24 20060101ALI20200210BHEP

Ipc: A61P 27/02 20060101ALI20200210BHEP

Ipc: A61K 9/00 20060101ALI20200210BHEP

Ipc: A61K 39/00 20060101ALI20200210BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/724 20060101ALI20201001BHEP

Ipc: A61P 25/00 20060101ALI20201001BHEP

Ipc: A61K 9/00 20060101ALI20201001BHEP

Ipc: A61P 27/14 20060101ALI20201001BHEP

Ipc: A61P 29/00 20060101ALI20201001BHEP

Ipc: C07K 16/24 20060101ALI20201001BHEP

Ipc: A61K 39/00 20060101ALI20201001BHEP

Ipc: A61P 43/00 20060101ALI20201001BHEP

Ipc: A61P 27/02 20060101ALI20201001BHEP

Ipc: C07K 14/54 20060101ALI20201001BHEP

Ipc: A61K 38/20 20060101ALI20201001BHEP

Ipc: A61K 45/06 20060101ALI20201001BHEP

Ipc: A61P 27/04 20060101ALI20201001BHEP

Ipc: A61K 31/728 20060101ALI20201001BHEP

Ipc: A61K 38/17 20060101AFI20201001BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210127

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009063874

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1410140

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210815

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210714

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1410140

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211115

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211014

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211014

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2892048

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009063874

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009063874

Country of ref document: DE

Representative=s name: SIMMONS & SIMMONS LLP, DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

26N No opposition filed

Effective date: 20220419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220109

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090109

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240201

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240129

Year of fee payment: 16

Ref country code: GB

Payment date: 20240129

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240122

Year of fee payment: 16

Ref country code: FR

Payment date: 20240125

Year of fee payment: 16